首页 产品中心
  • Cilengitide
    • EMD 12197,EMD-85189,EMD-121974,NSC-707544,D03497
    货号: abs811149
    CAS号: 188968-51-6
    分子式: C27H40N8O7
    分子量: 588.66
    产品说明书
    分享:
    货号-规格 货期 价格 数量
    abs811149-5mg 4周 ¥1490.00
    - +
    abs811149-10mg 4周 ¥2109.00
    - +
    abs811149-50mg 4周 ¥6671.00
    - +
    大包装询价
    产品描述
    描述

    Cilengitide is a cyclic Arg-Gly-Asp peptide with potential antineoplastic activity. Cilengitide binds to and inhibits the activities of the alpha(v)beta(3) and alpha(v)beta(5) integrins, thereby inhibiting endothelial cell-cell interactions, endothelial cell-matrix interactions, and angiogenesis.

    纯度
    >98%
    储存/保存方法
    Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution.
    基本信息
    别名
    EMD 12197,EMD-85189,EMD-121974,NSC-707544,D03497
    可溶性/溶解性
    DMSO: ≥ 44 mg/mL; H2O: ≥ 32 mg/mL
    生物活性
    靶点
    Integrin
    In vitro(体外研究)
    Cilengitide (EMD 121974) is the αvβ3 and αvβ5 integrin receptor antagonist. In cell adhesion studies assessing the human melanoma M21 or UCLA-P3 human lung carcinoma cell lines, Cilengitide inhibits integrin-mediated binding to vitronectin with IC50s of 0.4 and 0.4 μM. In vitro treatment of Cilengitide, at a concentration greater than 1 µM, shows concentration- and time-dependent cytotoxic effects. However, lower doses of Cilengitide monotherapy (0.1 and 0.5 µM) does not elicit the effective death of the both U87MG and U251MG cells. Significant cytotoxic effects are observed in the U87MG cells with the addition of 1 µM Cilengitide in combination with Belotecan monotherapy at concentration of 6.25 nM. Higher concentrations of Cilengitide (5 and 25 µM) does not significantly increase cell death in the U87MG and U251MG compare to a lower concentration of Cilengitide (1 µM).
    In vivo(体内研究)
    In nude mice bearing M21-L melanoma tumors, Cilengitide dose i.p. at 10, 50, and 250 μg three times per week demonstrated inhibition of tumor growth with a reduction in both tumor volume (55%, 75%, and 89%, respectively) and tumor weight (23%, 38%, and 61%, respectively), when compared to controls. In the rat model studied, the systemic pharmacokinetics of i.p. Cilengitide are not affected by ILP with Cilengitide alone or ILP with Cilengitide plus Melphalan, TNF or both. Systemic Cilengitide levels reach around 20 µg/mL (approximately 35 µM) within 10 min of i.p. administration and continued to rise to approximately 40 µg/mL (approximately 70 µM) in the first hour. Thereafter Cilengitide levels in serum dropped with an elimination half-life of 2.1 hr.
    温馨提示:本产品仅作科研实验使用,不支持临床等研究
    • 实验方法 实验条件
      0张,还能上传 8 提交
          提示: 尊敬的客户您好,如果您对我们的产品有什么疑问或想要了解的,可以点击“我要提问”按钮填写您的疑问。
          提交不成功?请联系info@absin.cn。
          我要提问

      促销资讯 更多

        订购信息
        您可以从我们的授权经销商处购买absin产品或获得技术支持。若要查看您所在地区的经销商,请从以下的下拉列表中选择。
        GO
        • 0